TG Therapeutics, Inc.

Item 8.01. Other Events On May 27, 2026, TG Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BRIUMVI® (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (RMS). A copy of the press release is being filed herewith as Exhibit 99.1 and incorporated into this Item by reference. Item 9.01. Financial Statements and Exhibits. Exhibit No. Description ────────────────────────────────────────────────────────────────────────────────────────────────── 99.1 Press release issued by TG Therapeutics, Inc., dated May 27, 2026. Exhibit 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL.